RESEARCH-USE BIOSIMILAR ANTIBODY
Ocrelizumab
Monoclonal antibody · IgG1
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC).
TARGETMS4A1
YMonoclonal antibody
CATALOGSC-BS-322
CATALOG NUMBERSC-BS-322
MOLECULAR WEIGHTApprox. 145.82 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC).
Ocrelizumab is a recombinant research-use antibody directed against MS4A1.